Thapsigargin, Inhibitor of Sarco-Endoplasmic Ca2+-ATPase, Effectively Suppresses the Expression of S100A4 Protein in Human Breast Cancer Cell Line


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

Thapsigargin (SERCA ATPase inhibitor) inhibited the S100A4 metastatic marker expression in MDA-MB231 breast cancer cells. We found that S100A4 gene transcription is regulated by Ca2+ signaling pathways. We found that the synthesis of S100A4 mRNA and S100A4 protein in MDA-MB231 cells was effectively suppressed by thapsigargin at a concentration of 0.4–4 μM with retaining cell viability. We assume that the change in the gene transcription in response to disturbance of Ca2+ homeostasis is directly involved in the remodeling of Ca2+ signaling pathways.

Авторлар туралы

A. Kotnova

Engelhardt Institute of Molecular Biology,
Russian Academy of Sciences

Хат алмасуға жауапты Автор.
Email: alina_kotnova@mail.ru
Ресей, Moscow, 119991

B. Lyanova

Engelhardt Institute of Molecular Biology,
Russian Academy of Sciences

Email: alina_kotnova@mail.ru
Ресей, Moscow, 119991

E. Dukhanina

Engelhardt Institute of Molecular Biology,
Russian Academy of Sciences

Email: alina_kotnova@mail.ru
Ресей, Moscow, 119991

T. Portseva

Engelhardt Institute of Molecular Biology,
Russian Academy of Sciences

Email: alina_kotnova@mail.ru
Ресей, Moscow, 119991

Yu. Ilyin

Engelhardt Institute of Molecular Biology,
Russian Academy of Sciences

Email: alina_kotnova@mail.ru
Ресей, Moscow, 119991

S. Georgieva

Engelhardt Institute of Molecular Biology,
Russian Academy of Sciences

Email: alina_kotnova@mail.ru
Ресей, Moscow, 119991

A. Stepchenko

Engelhardt Institute of Molecular Biology,
Russian Academy of Sciences

Email: alina_kotnova@mail.ru
Ресей, Moscow, 119991

E. Pankratova

Engelhardt Institute of Molecular Biology,
Russian Academy of Sciences

Email: alina_kotnova@mail.ru
Ресей, Moscow, 119991

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Pleiades Publishing, Inc., 2019